

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-100391-PIP01-21-M01

### **Scope of the Application**

#### **Active Substance(s)**

Highly purified single-stranded, 5'-capped mRNA encoding full length SARS-CoV2 spike protein (BNT162b2); TOZINAMERAN

#### **Condition(s)**

Prevention of Coronavirus disease 2019 (COVID-19)

#### **Pharmaceutical Form(s)**

Concentrate for dispersion for injection, Dispersion for injection

#### **Route(s) of Administration**

Intramuscular use

#### **Name / Corporate name of the PIP applicant**

BioNTech Manufacturing GmbH

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, BioNTech Manufacturing GmbH submitted to the licensing authority on 21/12/2021 17:12 GMT an application for a

The procedure started on 06/01/2022 12:24 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom  
[gov.uk/mhra](https://gov.uk/mhra)

## Final Decision Letter

MHRA-100391-PIP01-21-M01

Of 19/01/2022 16:28 GMT

On the adopted decision for Highly purified single-stranded, 5'-capped mRNA encoding full length SARS-CoV2 spike protein (BNT162b2); TOZINAMERAN (MHRA-100391-PIP01-21-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a for Highly purified single-stranded, 5'-capped mRNA encoding full length SARS-CoV2 spike protein (BNT162b2); TOZINAMERAN, Concentrate for dispersion for injection, Dispersion for injection , Intramuscular use .

This decision is addressed to BioNTech Manufacturing GmbH, An der Goldgrube 12, Mainz, Germany, 55131

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Not applicable
----------------

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Prevention of Coronavirus disease 2019 (COVID-19)
---

#### 2.2 Indication(s) targeted by the PIP:

Prevention of Coronavirus disease 2019 (COVID-19)
---

### 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age

### 2.4 Pharmaceutical Form(s):

Concentrate for dispersion for injection; Dispersion for injection

### 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable
Non-Clinical Studies	0	Not applicable
Clinical Studies	4	Study 1 (C4591001) Double blind dose-finding study of safety, tolerability, and immunogenicity of 2 different SARS-CoV-2 vaccine candidates (adults only) (part 1) and placebo-controlled efficacy, safety and immunogenicity study of highly purified single-stranded, 5'-capped mRNA encoding full length SARS-CoV-2 spike protein (BNT162b2) in adolescents from 12 years to less than 18 years of age (and adults) (part 2) for prevention of COVID-19 Study 2 (C4591007) Double blind, controlled, dose-finding safety, tolerability, and immunogenicity study of tozinameran in paediatric subjects from 6 months to less than 12 years of age for prevention of COVID-19. Study 3 Open, controlled, dose-finding, safety and immunogenicity study of tozinameran in children from birth to less than 6 months of age for prevention of COVID-19 Study 4 Open label, uncontrolled, safety and immunogenicity study of tozinameran in immunocompromised children from birth to less than 18 years of age for prevention of COVID-19.
Extrapolation, Modeling & Simulation Studies	0	Not applicable
Other Studies	0	Not applicable
Other Measures	0	Not applicable

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	No
<b>Date of completion of the paediatric investigation plan:</b>	31/07/2024
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes